Predictive factors for visual outcome to intravitreal bevacizumab in young chinese patients with myopic choroidal neovascularization

Retina

Volumn 31, Issue 9, 2011, Pages 1835-1840

  Kuo, Jane Zea Chin ^a,b,c   Ong, Frank Shih Chang ^b   Yeung, Ling ^a,c   Wu, Wei Chi ^a,c   Chen, Yen Po ^a,c   Wang, Nan Kai ^a,c   Lai, Chi Chun ^a,c  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

bevacizumab; Chinese; choroidal neovascularization; pathologic myopia; young

Indexed keywords

BEVACIZUMAB;

ADOLESCENT; ADULT; AGED; ARTICLE; CATARACT; CHINESE; CLINICAL EXAMINATION; CONTROLLED STUDY; ENDOPHTHALMITIS; FEMALE; FLUORESCENCE ANGIOGRAPHY; GLAUCOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MYOPIA; MYOPIC CHOROIDAL NEOVASCULARIZATION; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; RETINA DETACHMENT; RETINA FOVEA; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISION; VISUAL ACUITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ASIAN CONTINENTAL ANCESTRY GROUP; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; MYOPIA, DEGENERATIVE; PHOTOGRAPHY; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; YOUNG ADULT;

EID: 80053353067     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31821ba2dc     Document Type: Article

References (35)

1. Xu L, Wang Y, Li Y, et al. Causes of blindness and visual impairment in urban and rural areas in Beijing: The Beijing Eye Study. Ophthalmology 2006;113:1134.e1-e11.
2. Avila MP, Weiter JJ, Jalkh AE, et al. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 1984;91:1573-1581.
3. Hayashi K, Ohno-Matsui K, Teramukai S, et al. Photodynamic therapy with verteporfin for choroidal neovascularization of pathologic myopia in Japanese patients: Comparison with nontreated controls. Am J Ophthalmol 2008;145:518-526.
4. Soubrane G. Choroidal neovascularization in pathologic myopia: Recent developments in diagnosis and treatment. Surv Ophthalmol 2008;53:121-138.
5. Tabandeh H, FlynnHWJr., Scott IU, et al. Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularization. Ophthalmology 1999; 106:2063-2067.
6. Yoshida T, Ohno-Matsui K, Ohtake Y, et al. Long-term visual prognosis of choroidal neovascularization in high myopia: A comparison between age groups. Ophthalmology 2002;109: 712-719.
7. Hotchkiss ML, Fine SL. Pathologic myopia and choroidal neovascularization. Am J Ophthalmol 1981;91:177-183.
8. Grossniklaus HE, Green WR. Pathologic findings in pathologic myopia. Retina 1992;12:127-133.
9. Curtin BJ, Karlin DB. Axial length measurements and fundus changes of the myopic eye. Am J Ophthalmol 1971;71:42-53.
10. Cohen SY, Laroche A, Leguen Y, et al. Etiology of choroidal neovascularization in young patients. Ophthalmology 1996; 103:1241-1244.
11. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial-VIP report no. 1. Ophthalmology 2001; 108:841-852.
12. Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no. 3. Ophthalmology 2003;110:667-673.
13. Lam DS, Chan WM, Liu DT, et al. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: A prospective series of 1 and 2 year follow up. Br J Ophthalmol 2004;88:1315-1319.
14. xer-Siegel R, Ehrlich R, Weinberger D, et al. Photodynamic therapy of subfoveal choroidal neovascularization in high myopia in a clinical setting: Visual outcome in relation to age at treatment. Am J Ophthalmol 2004;138:602-607.
15. Ruiz-Moreno JM, Amat P, Montero JA, Lugo F. Photodynamic therapy to treat choroidal neovascularisation in highly myopic patients: 4 years' outcome. Br J Ophthalmol 2008;92:792-794.
16. Montero JA, Ruiz-Moreno JM. Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation. Br J Ophthalmol 2003;87:173-176.
17. Arias L, Planas N, Prades S, et al. Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results. Br J Ophthalmol 2008;92:1035-1039.
18. Hayashi K, Ohno-Matsui K, Shimada N, et al. Intravitreal bevacizumab on myopic choroidal neovascularization that was refractory to or had recurred after photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 2009;247:609-618.
19. Hernandez-RojasML, Quiroz-Mercado H, Dalma-Weiszhausz J, et al. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 2007;27:707-712.
20. Sakaguchi H, Ikuno Y, Gomi F, et al. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 2007;91: 161-165.
21. Yamamoto I, Rogers AH, Reichel E, et al. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 2007;91:157-160.
22. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. Br J Ophthalmol 2009;93: 150-154.
23. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 2009; 147:84-93.
24. Ikuno Y, Sayanagi K, Soga K, et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: One-year results. Am J Ophthalmol 2009;147: 94-100.
25. Ruiz-Moreno JM, Montero JA, Gomez-Ulla F, Ares S. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome. Br J Ophthalmol 2009;93:448-451.
26. Cohen SY. Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia. Retina 2009;29:1062-1066.
27. Yoshida T, Ohno-Matsui K, Yasuzumi K, et al. Myopic choroidal neovascularization: A 10-year follow-up. Ophthalmology 2003;110:1297-1305.
28. Hayashi K, Ohno-Matsui K, Yoshida T, et al. Characteristics of patients with a favorable natural course of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2005; 243:13-19.
29. Kojima A, Ohno-Matsui K, Teramukai S, et al. Estimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia. Graefes Arch Clin Exp Ophthalmol 2006;244:1474-1479.
30. Ikuno Y, Nagai Y, Matsuda S, et al. Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol 2010;149:140-146.
31. Lin LL, Shih YF, Hsiao CK, Chen CJ. Prevalence of myopia in Taiwanese schoolchildren: 1983 to 2000. Ann Acad Med Singapore 2004;33:27-33.
32. Hayashi K, Ohno-Matsui K, Futagami S, et al. Choroidal neovascularization in highly myopic eyes after cataract surgery. Jpn J Ophthalmol 2006;50:345-348.
33. Sebag J and Yee KMP: Vitreous - from biochemistry to clinical relevance. In: Duane's Foundations of Clinical Ophthalmology (W Tasman and EA Jaeger, eds). Lippincott Williams & Wilkins, Philadelphia, 2006, Vol 1, Ch 16 (CD-ROM).
34. Giblin FJ, Quiram PA, Leverenz VR, et al. Enzyme-induced posterior vitreous detachment in the rat produces increased lens nuclear pO2 levels. Exp Eye Res 2009;88:286-292.
35. Quiram PA, Leverenz VR, Baker RM, et al. Microplasmininduced posterior vitreous detachment affects vitreous oxygen levels. Retina 2007;27:1090-1096.